en
Scientific article
Open access
English

Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics

Published inAmerican Heart Journal, vol. 220, p. 203-212
Publication date2020
Abstract

People living with human immunodeficiency virus (PLHIV) are at higher risk of atherosclerotic cardiovascular disease (ASCVD) due to traditional and HIV- or antiretroviral treatment (ART)-related risk factors. The use of high-intensity statin therapy is often limited by comorbidities and drug–drug interactions with ART. Herein, we present the design and baseline characteristics of the BEIJERINCK study, which will assess the safety and efficacy of evolocumab in PLHIV and hypercholesterolemia/mixed dyslipidemia.

Research group
Citation (ISO format)
BOCCARA, Franck et al. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. In: American Heart Journal, 2020, vol. 220, p. 203–212. doi: 10.1016/j.ahj.2019.11.004
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0002-8703
177views
69downloads

Technical informations

Creation10/30/2020 8:21:00 PM
First validation10/30/2020 8:21:00 PM
Update time03/16/2023 12:55:19 AM
Status update03/16/2023 12:55:17 AM
Last indexation05/06/2024 7:49:18 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack